British COVID-19 drug Sotrovimab approved: effective against Omicron
- Fasting for 16 hours a day may increase the risk of cardiovascular death by 91%
- FDA Approves Groundbreaking Gene Therapy from UK’s Orchard Therapeutics
- Breakthrough in CAR-T therapy: Tumors almost completely disappear in just 5 days
- Adapalene can effectively activate senescence in prostate cancer cells and increase NK cell anti-tumor activity
- mRNA Therapy Unveils Hidden Cancer Cells: BioNTech’s IL-2 Breakthrough
- “Blood Test for Cancer”: Accuracy Up to 83% for Colorectal Cancer
British COVID-19 drug Sotrovimab approved: effective against Omicron
- Long COVID Brain Fog: Blood-Brain Barrier Damage and Persistent Inflammation
- Japan: Over 10,000 Applications for Health Damage from COVID-19 Vaccines
- FDA has mandated a top-level black box warning for all marketed CAR-T therapies
- ‘Elixir of Immortality’ Nicotinamide Riboside (NR) Virtually No Effect
- Can people with high blood pressure eat peanuts?
- What is the difference between dopamine and dobutamine?
- How long can the patient live after heart stent surgery?
British COVID-19 drug Sotrovimab approved: effective against Omicron.
Recently, the new coronavirus mutant strain Omicron reported in South Africa has attracted global attention, and the WHO has assessed its overall global risk as “very high”, which means that it may spread widely in the world.
According to foreign media reports, a study published on the preprint server “BioRxiv” showed that a COVID-19 monoclonal antibody drug called “Sotrovimab” is effective against Omicron.
The report pointed out that “Sotrovimab” was developed by the British GlaxoSmithKline (GSK) and the American biotechnology company Vir Biotechnology (VIR).
However, the research has not yet passed peer review.
The research was conducted on a pseudovirus of all variants of the new coronavirus, including key mutations carried by the Omicron strain.
The results showed that the “Sotrovimab” monoclonal antibody was still active against Omicron strain.
Vir CEO Dr. George Scangos (George Scangos) said in a statement that “Sotrovimab” is specially designed.
When the design points out, it takes into account the possible mutation of the virus, and the antibody targets the spike protein. The part where mutations are unlikely to occur.
It is worth mentioning that due to the high infectivity and ability of the Omicron strain to evade vaccine protection, many vaccine companies are developing new vaccines against it.
American vaccine company Moderna CEO Stephane Bancel (Stephane Bancel) has stated that the existing vaccines will be far less effective in dealing with the Omicron strain, and there will be a substantial decline.
At present, the British Medicines and Medical Products Regulatory Agency has approved “Sotrovimab” for the treatment of COVID-19. In addition, the United States, Japan and other countries have also approved “Sotrovimab” for the treatment of COVID-19s.
British COVID-19 drug Sotrovimab approved: effective against Omicron.
(source:internet, reference only)
Disclaimer of medicaltrend.org
Important Note: The information provided is for informational purposes only and should not be considered as medical advice.